Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $21 from $23 and keeps a Buy rating on the shares after discussing the progress of the company’s DMD clinical programs. The firm remains enthusiastic about ENTR-601-44 and ENTR-601-45, looking forward to the respective clinical trial starts in the U.S. and ex-U.S. regions, though also acknowledges the latter’s clinical trajectory could be “long and winding”, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
- Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
- Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)
- Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
- Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment